Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates

Fig. 4

The long-term stability of ARCoV formulations. After storage for 0, 1, 2, 3, 4, and 6 months at 2–8 °C, all formulations were tested for mRNA purity (a), mRNA encapsulation efficiency (b), particle size and polydispersity index (PDI) (c). Data is represented as mean ± SEM (n = 8) for encapsulation efficiency, and (n = 3) for particle size and PDI. d Mice were immunized i.m. with two doses of Placebo (n = 5), fresh ARCoV (n = 10) or stored ARCoV (n = 10), with an interval of 14 days. The SARS-CoV-2 RBD-specific IgG antibody titers of the immunized mice on day 21 after initial vaccination was determined by ELISA. Symbols represent individual animals. Data are shown as mean ± SEM. The dashed lines indicate the limit of detection. Statistical significance was calculated using a Student’s t test (n.s. not significant)

Back to article page